The global influenza A infections market size is estimated to be valued at USD 744.2 Million in 2025. It is projected to reach a valuation of USD 909.1 Million by 2032, by exhibiting a CAGR of 2.9% throughout the forecast period (2025-2032).
Influenza A virus, or IAV, is a contagious virus that can cause seasonal flus or acute respiratory illnesses in vulnerable populations. The vulnerability of adults older than 65 years of age, as well as individuals with chronic pulmonary disorders, is expected to be the major growth driver of the influenza A infections market.
However, complications arising in vaccine production due to constant mutations of the virus can be a challenge to the market growth.
Key Market Insights
The influenza A infections market growth is anticipated to be driven by the high number of flu infections and development of interventional therapies against influenza A.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/influenza-a-infections-market
Influenza A Infections Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 744.2 Million |
|
Estimated Value by 2032 |
USD 909.1 Million |
|
Growth Rate |
2.9% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD million) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The high efficacy associated with high-dose inactivated flu vaccines is expected to be a major driver of the market growth. On October 27, 2025, randomized trials of two vaccines – DANFLU2 and GALFLU were assessed in adults in 2022-2025 and 2023-2025 seasons. It resulted in only half the patients undergoing hospitalization who received the high-dose vaccine in comparison to 60% of the patients in hospitals who had undertaken the standard flu vaccine. The study was led by the Copenhagen University Hospital in Denmark and published on October 17, 2025.
The development of a central antigen, AC-Anhui, for combating all subtypes of the H5 influenza virus by researchers at the Erasmus University Medical Center in the Netherlands, can also augur favorably for the market growth. The study published on October 27, 2025, stated the moderate efficacy of AC-Anhui against the H5N6 variant and a high success rate against the H5N1 variant.
Market Opportunity: Government Vaccination Programs
The establishment of government vaccination programs for improving public confidence and increasing the uptake of vaccine admissions among the masses can be a lucrative opportunity for the market. The allocation of funding to health agencies to serve the public through mobile immunization clinics and retail pharmacies can bolster the market growth.
Market Challenge: Rise in Vaccine Hesitancy
The growing trend of vaccine hesitancy, fueled by misinformation and fatigue from the COVID-19 pandemic, can be challenging for the market growth. This can be attributed to distrust of the latest formulations and an underestimation of the severity of the latest flu variants. The high need for proactive awareness campaigns to improve herd immunity and increase compliance among young adults can bode well for the influenza A infections market.
Analyst’s View
Recent Developments
AstraZeneca launched FluMist Home, a DTC home delivery of the self-administered FluMist vaccine, on August 15, 2025. The vaccine is approved by the U.S. FDA for adults between 18-49 years of age and be administered to individuals aged between 2-17 years. It will be available in 34 states.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :